论文部分内容阅读
目的:评价外用盐酸氨酮戊酸散光动力疗法治疗尖锐湿疣的临床疗效。方法:采用开放、高频电离子平行对照的临床研究方法。治疗组28例患者,采用外用盐酸氨酮戊酸散光动力疗法,一周治疗一次,连续治疗三周;对照组37例患者,采用高频电离子切割治疗。两组患者均在末次治疗后第一周进行疗效评价及不良反应观察,第4、8、12周观察复发率。结果:1例患者因三次外用盐酸氨酮戊酸散光动力疗法后疣体脱落而提前终止试验,64例患者完成了全部的随访。在末次治疗后1周时疣体清除率:治疗组为96.4%,对照组为100%,其中尿道口的疣体清除率:两组均为100%;非尿道口的疣体清除率:治疗组为91.67%,对照组为100%,无论是尿道口还是非尿道口尖锐湿疣,两组的疗效无统计学差异(P>0.05)。治疗后随访12周的复发率:治疗组为6.86%,对照组24.32%,P<0.05;其中尿道口的复发率:治疗组为5.88%,对照组42.86%,P<0.05;非尿道口的疣体清除率:治疗组为8.33%,对照组为20%,P<0.05。两组均具有统计学差异。两组均没有出现系统不良反应,局部不良反应率:治疗组为7.14%,主要为轻度糜烂、疼痛、渗液;对照组为48.65%,主要为溃疡、疼痛、疤痕等,治疗组不良反应发生率均明显低于对照组,差异有统计学意义。结论:ALA-PDT清除率高,复发率低,安全,耐受性好,无明显副作用,可作为尿道口CA治疗首选。
OBJECTIVE: To evaluate the clinical efficacy of topical aspirin hydrochloride astigmatism in the treatment of condyloma acuminatum. Methods: The clinical research methods of open and high frequency ion-parallels control were used. Twenty-eight patients in the treatment group were treated with topiramate-HCl astigmatism therapy once a week for three weeks. In the control group, 37 patients were treated with high-frequency iontophoresis. The two groups of patients in the first week after the last treatment efficacy evaluation and adverse reactions were observed, the 4th, 8th and 12th weeks observed the recurrence rate. RESULTS: One patient discontinued premature termination of the wart after three topical exenatide hydrocortisone therapy and 64 patients completed the full follow-up. At 1 week after the last treatment, the rate of wart clearance was 96.4% in the treatment group and 100% in the control group, and the rate of wart clearance in the urethra was 100% in both groups; the rate of wart clearance in the non-urethral orifice was Group 91.67%, control group 100%, both urethral or non-urethral orifice condyloma acuminatum, the two groups had no statistically significant difference (P> 0.05). The recurrence rate after 12 weeks of treatment was 6.86% in the treatment group and 24.32% in the control group, P <0.05. The recurrence rate of the urethra was 5.88% in the treatment group and 42.86% in the control group, P <0.05; Wart clearance rates were 8.33% in the treatment group and 20% in the control group, P <0.05. There was statistical difference between the two groups. Systemic adverse reactions were not observed in both groups. The rate of local adverse reactions was 7.14% in the treatment group, which was mainly mild erosion, pain and exudate. The control group was 48.65%, mainly including ulcer, pain and scar. The adverse reactions in the treatment group The incidence was significantly lower than the control group, the difference was statistically significant. Conclusion: ALA-PDT has high clearance rate, low recurrence rate, good safety and tolerability, and no obvious side effects. It can be used as the first choice of urethral CA.